GWM
RARE icon

Geneos Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Geneos Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27
Closed -$982 – 3022
2025
Q2 		$982 Sell
27
-131
-83% -$4.72K ﹤0.01% 2988
2025
Q1 		$5.72K Buy
158
+121
+327% +$5.03K ﹤0.01% 2721
2024
Q4 		$1.56K Sell
37
-14
-27% -$695 ﹤0.01% 2675
2024
Q3 		$2.83K Buy
+51
New +$2.6K ﹤0.01% 2214
2018
Q3 		– Sell
-35
Closed -$2K – 2444
2018
Q2 		$2K Hold
35
– – ﹤0.01% 2127
2018
Q1 		$1K Hold
35
– – ﹤0.01% 2121
2017
Q4 		$1K Hold
35
– – ﹤0.01% 2120
2017
Q3 		$1K Sell
35
-30
-46% -$1.78K ﹤0.01% 2070
2017
Q2 		$4K Buy
65
+23
+55% +$1.39K ﹤0.01% 1806
2017
Q1 		$2K Sell
42
-7
-14% -$533 ﹤0.01% 1918
2016
Q4 		$3K Buy
49
+26
+113% +$1.84K ﹤0.01% 1784
2016
Q3 		$1K Buy
+23
New +$1.47K ﹤0.01% 1913
2016
Q2 		– Sell
-33
Closed -$2K – 1837
2016
Q1 		$2K Buy
+33
New +$2.16K ﹤0.01% 1682

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geneos Wealth Management's RARE Position: Q3 2025 in Review

Geneos Wealth Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 27 shares — an estimated $982 sold.

Geneos Wealth Management first reported a position in RARE in Q1 2016 and held it in 13 quarters. The position peaked at $5.72K in Q1 2025. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Geneos Wealth Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 27 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $982.
  • Geneos Wealth Management first reported a position in Ultragenyx Pharmaceutical in Q1 2016 and held it in 13 quarters.
  • Geneos Wealth Management's Ultragenyx Pharmaceutical position peaked at $5.72K in Q1 2025.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.